ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2026)
ARS Pharmaceuticals recorded quarterly FCF Margin of 198.17% in Q1 2026, down 28.0% quarter-over-quarter from 154.82% in Q4 2025, and up 31398.0% year-over-year from N/an in Q1 2025.
ARS Pharmaceuticals' FCF Margin history runs 5 years deep, the most recent figure standing at 198.17% for Q1 2026.
- In Q1 2026, FCF Margin rose 31398.0% year-over-year to 198.17%; the TTM figure through Mar 2026 stood at 177.11% (down 15544.0% YoY), while the FY2025 annual figure was 203.14%, down 21771.0% from the prior year.
- FCF Margin came in at 198.17% for Q1 2026 at ARS Pharmaceuticals, down from 154.82% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 47.96% in Q4 2024 to a low of 166990.0% in Q2 2023.
- A 5-year average of 18389.82% and a median of 703.77% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin tumbled 16549151 bps in 2023 and surged 16555080 bps in 2024, its largest moves.
- ARS Pharmaceuticals' FCF Margin stood at 3044.97% in 2022, then tumbled by 5384 bps to 166990.0% in 2023, then soared by 100 bps to 47.96% in 2024, then slumped by 423 bps to 154.82% in 2025, then retreated by 28 bps to 198.17% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 198.17%, 154.82%, and 127.77% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | ARS Pharmaceuticals | 900.62 Mn | 699.65 Mn | - | -198.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -198.17% |
| Dec 31, 2025 | -154.82% |
| Sep 30, 2025 | -127.77% |
| Jun 30, 2025 | -288.61% |
| Mar 31, 2025 | -512.14% |
| Dec 31, 2024 | 48.17% |
| Sep 30, 2024 | -706.33% |
| Jun 30, 2024 | -1,463.40% |
| Jun 30, 2023 | -166,990.00% |
| Mar 31, 2023 | -63,110.00% |
| Sep 30, 2022 | -2,983.60% |
| Jun 30, 2022 | -1,507.76% |
| Mar 31, 2022 | -1,047.66% |